FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028080341> ?p ?o ?g. }

• W3028080341 abstract "A 3.5 year old Hispanic female presented with signs and symptoms concerning for MPS II (Hunter Syndrome). The diagnosis of MPS II was confirmed by enzyme and molecular testing. Genetic evaluation revealed undetectable plasma iduronate-2-sulfatase enzyme activity and an inversion between intron 7 of the IDS gene and a region near exon 3 of IDS-2. This inversion is the molecular cause for approximately 8% of cases of MPS II and often results in a severe phenotype. X-inactivation studies revealed an inactivation ratio of 100:0. Given the patient’s undetectable enzyme level, in combination with a severe IDS gene mutation, classic features at time of presentation, and the significantly skewed X inactivation, there was concern that she was at high risk of developing high and sustained antibody titers to idursulfase which would limit her benefit from enzyme replacement therapy (ERT). Anti-drug neutralizing antibodies to idursulfase have been associated with reduced systemic exposure to idursulfase and poorer clinical outcomes. Therefore, the decision was made to concurrently treat the patient with immune tolerance induction therapy during the first month of treatment with idursulfase in order to decrease the risk of developing high sustained antibody titers. The immune tolerance induction protocol consisted of rituximab weekly for four weeks, methotrexate three times a week for three weeks and monthly IVIG through B-cell and immunoglobulin recovery. Immune tolerance induction was initiated concurrently with the start of ERT. The patient had no significant adverse effects related to undergoing immune tolerance induction therapy and two and half years later is doing well with significantly reduced urine glycosaminoglycans and very low anti-drug antibody titers. This immune tolerance induction protocol could be considered for other patients with MPS II as well as patients with other lysosomal storage disorders who are starting on enzyme replacement therapy and are at high risk of developing neutralizing anti-drug antibodies." @default.
• W3028080341 created "2020-05-29" @default.
• W3028080341 creator A5008038245 @default.
• W3028080341 creator A5011057075 @default.
• W3028080341 creator A5037775852 @default.
• W3028080341 creator A5048344117 @default.
• W3028080341 creator A5059134248 @default.
• W3028080341 creator A5074432325 @default.
• W3028080341 creator A5083624578 @default.
• W3028080341 date "2020-05-21" @default.
• W3028080341 modified "2023-10-14" @default.
• W3028080341 title "Immune Modulation for Enzyme Replacement Therapy in A Female Patient With Hunter Syndrome" @default.
• W3028080341 cites W1571262084 @default.
• W3028080341 cites W1982093927 @default.
• W3028080341 cites W1988435252 @default.
• W3028080341 cites W1993027304 @default.
• W3028080341 cites W1994657204 @default.
• W3028080341 cites W2019208481 @default.
• W3028080341 cites W2020409398 @default.
• W3028080341 cites W2022749609 @default.
• W3028080341 cites W2027030407 @default.
• W3028080341 cites W2029840709 @default.
• W3028080341 cites W2034511507 @default.
• W3028080341 cites W2091858933 @default.
• W3028080341 cites W2096131321 @default.
• W3028080341 cites W2112711488 @default.
• W3028080341 cites W2113874233 @default.
• W3028080341 cites W2117234036 @default.
• W3028080341 cites W2141974903 @default.
• W3028080341 cites W2148045371 @default.
• W3028080341 cites W2150999708 @default.
• W3028080341 cites W2166039127 @default.
• W3028080341 cites W2168225099 @default.
• W3028080341 cites W2170673898 @default.
• W3028080341 cites W2194998340 @default.
• W3028080341 cites W2589172623 @default.
• W3028080341 cites W2610876835 @default.
• W3028080341 cites W2618390676 @default.
• W3028080341 cites W2621222499 @default.
• W3028080341 cites W2691728476 @default.
• W3028080341 cites W2730806912 @default.
• W3028080341 cites W2745716847 @default.
• W3028080341 cites W2761204945 @default.
• W3028080341 cites W2912843979 @default.
• W3028080341 cites W2947475941 @default.
• W3028080341 cites W2970703882 @default.
• W3028080341 doi "https://doi.org/10.3389/fimmu.2020.01000" @default.
• W3028080341 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7253587" @default.
• W3028080341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32508845" @default.
• W3028080341 hasPublicationYear "2020" @default.
• W3028080341 type Work @default.
• W3028080341 sameAs 3028080341 @default.
• W3028080341 citedByCount "7" @default.
• W3028080341 countsByYear W30280803412020 @default.
• W3028080341 countsByYear W30280803412021 @default.
• W3028080341 countsByYear W30280803412022 @default.
• W3028080341 countsByYear W30280803412023 @default.
• W3028080341 crossrefType "journal-article" @default.
• W3028080341 hasAuthorship W3028080341A5008038245 @default.
• W3028080341 hasAuthorship W3028080341A5011057075 @default.
• W3028080341 hasAuthorship W3028080341A5037775852 @default.
• W3028080341 hasAuthorship W3028080341A5048344117 @default.
• W3028080341 hasAuthorship W3028080341A5059134248 @default.
• W3028080341 hasAuthorship W3028080341A5074432325 @default.
• W3028080341 hasAuthorship W3028080341A5083624578 @default.
• W3028080341 hasBestOaLocation W30280803411 @default.
• W3028080341 hasConcept C104317684 @default.
• W3028080341 hasConcept C111599444 @default.
• W3028080341 hasConcept C126322002 @default.
• W3028080341 hasConcept C159654299 @default.
• W3028080341 hasConcept C197934379 @default.
• W3028080341 hasConcept C203014093 @default.
• W3028080341 hasConcept C22889606 @default.
• W3028080341 hasConcept C2776225084 @default.
• W3028080341 hasConcept C2777702733 @default.
• W3028080341 hasConcept C2779134260 @default.
• W3028080341 hasConcept C2779969927 @default.
• W3028080341 hasConcept C2910638406 @default.
• W3028080341 hasConcept C32611913 @default.
• W3028080341 hasConcept C54355233 @default.
• W3028080341 hasConcept C71924100 @default.
• W3028080341 hasConcept C86803240 @default.
• W3028080341 hasConcept C8891405 @default.
• W3028080341 hasConceptScore W3028080341C104317684 @default.
• W3028080341 hasConceptScore W3028080341C111599444 @default.
• W3028080341 hasConceptScore W3028080341C126322002 @default.
• W3028080341 hasConceptScore W3028080341C159654299 @default.
• W3028080341 hasConceptScore W3028080341C197934379 @default.
• W3028080341 hasConceptScore W3028080341C203014093 @default.
• W3028080341 hasConceptScore W3028080341C22889606 @default.
• W3028080341 hasConceptScore W3028080341C2776225084 @default.
• W3028080341 hasConceptScore W3028080341C2777702733 @default.
• W3028080341 hasConceptScore W3028080341C2779134260 @default.
• W3028080341 hasConceptScore W3028080341C2779969927 @default.
• W3028080341 hasConceptScore W3028080341C2910638406 @default.
• W3028080341 hasConceptScore W3028080341C32611913 @default.
• W3028080341 hasConceptScore W3028080341C54355233 @default.
• W3028080341 hasConceptScore W3028080341C71924100 @default.
• W3028080341 hasConceptScore W3028080341C86803240 @default.
• W3028080341 hasConceptScore W3028080341C8891405 @default.

• next